Goals and Activities:
-
Acquire conventional and novel biomarkers in biofluid (CSF, blood), brain images (PET, MRI), and other modalities (e.g., retinal imaging) in adjudicated participant groups.
- Analyze biomarkers to obtain standardized measures and support relevant funded Alzheimer’s disease (AD) research projects affiliated with the ADRC.
- Provide resources integrating multi-dimensional biomarkers data across all human subjects to assist and train ADRC researchers to investigate the underlying age-related drivers for AD.
- Disseminate our expertise and knowledge to support the AD community at large.
- Assays currently being run on ADRC samples (or available at DMPI to run on ADRC samples): CSF abeta40 and 42, tau & p-tau-181p (and plasma abeta 40 and 42 & p-tau-181p) on the Fujirebio Lumipulse platform; Quanterix HD-X platform multiplex assays for 1) NfL and GFAP; 2) Tau, NfL, UCH-L1, GFAP; and 3) Abeta40, Abeta42, GFAP, NfL
Available Resources:
- Duke Brain Imaging and Analysis Center
- UNC Biomedical Research Imaging Center
- Duke Molecular Physiology Institute
Core Leaders
![]() |
Weili Lin, PhDDixie Lee Boney Soo Distinguished Professor of Neurological Medicine, UNC |
|
![]() |
Allen Song, PhDProfessor in Radiology, Duke University |
Junior Associate Core Leader
![]() |
Miles Berger, MD, PhDAssociate Professor or Anesthesiology, Duke University |
Faculty:
Staff:
- Clinical Research Specialists (TBD)